
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Lux... Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.3001 | -9.06619135374 | 3.3101 | 3.81 | 2.3937 | 103399 | 3.31413092 | CS |
4 | 2.8299 | 1571.29372571 | 0.1801 | 3.81 | 0.11 | 17323099 | 0.20762582 | CS |
12 | 2.825 | 1527.02702703 | 0.185 | 3.81 | 0.11 | 13261487 | 0.23658718 | CS |
26 | 2.6201 | 671.992818671 | 0.3899 | 3.81 | 0.11 | 6115871 | 0.23653985 | CS |
52 | 1.18 | 64.4808743169 | 1.83 | 3.81 | 0.11 | 3137583 | 0.25077237 | CS |
156 | -13.49 | -81.7575757576 | 16.5 | 23.25 | 0.11 | 1183781 | 1.53975401 | CS |
260 | -121.94 | -97.5910364146 | 124.95 | 138 | 0.11 | 1287731 | 33.39469425 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.